Methotrexate shows promise for treating juvenile scleroderma

01/8/2013 | PhysiciansBriefing.com

More than 70% of juvenile localized scleroderma patients who took oral methotrexate were in clinical remission for a mean of 25 months, while 27.1% experienced remission while taking the drug, according to an Italian study in the Journal of the American Academy of Dermatology. Generally mild side effects were reported by 48.3% of respondents, but they didn't cause the patients to stop the medication.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR